Business
Medicenna Reports Compelling Results from Recurrent Glioblastoma Trial When Compared to an Eligibility-Matched Control Arm
Medicenna Reports Compelling Results from Recurrent Glioblastoma Trial When Compared to an...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Reports Compelling Results from Recurrent Glioblastoma Trial When Compared to an Eligibility-Matched Control Arm\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, Jan 13, 2020\n\n\n\nSurvival improvement of over 150% seen in MDNA55 subjects compared to a Synthetic Control Arm\n TORONTO and HOUSTON, Jan 13, 2020 /CNW/ - Medicenna Therapeutics Corp.  (\"Medicenna\" or \"the Company\") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that it has completed a retrospective study on subjects with recurrent Glioblastoma (rGBM) who matched eligibility requirements of subjects enrolled in the MDNA55-05 clinical trial. \nThis study was conducted to compare the survival of subjects treated with MDNA55, an interleukin-4 receptor (IL4R) targeted therapy, in the Phase 2b rGBM clinical trial versus matched patients (Synthetic Control Arm or SCA) recently treated using other approved therapies.  The SCA comprised of 81 rGBM patients receiving approved therapies including Avastin, Lomustine and Temozolomide with similar baseline features as patients treated in the MDNA55 trial such as age, tumor size, ineligibility for surgery, interleukin-4 receptor (IL4R) expression and other parameters known to affect survival.\n\"This first true apples-to-apples comparison of the data shows that a single treatment with MDNA55 has the ability to more than double the survival rates in patients with the most aggressive form of rGBM,\" said Dr. Fahar Merchant, President and CEO of Medicenna Therapeutics. \"We hope that these results are a watershed moment in the battle against this aggressive and fatal disease, and are particularly meaningful considering that an even modest improvement in survival of 25% has not been demonstrated by any of the approved treatments of rGBM in more than two decades.\" \nKey data from the study are summarized below and have been computed from the date of relapse rather than from the date of treatment in results previously reported by the Comp...